## What's hot

One way anova
One way anova
Kemal İnciroğlu

ANOVA-One Way Classification
ANOVA-One Way Classification
Sharlaine Ruth

Statistical analysis by iswar
Sampling distribution
Sampling distribution
swarna dey

Student t test
Student t test

Test of significance
Test of significance
Dr. Imran Zaheer

Posthoc
Posthoc

Parametric Statistical tests
Parametric Statistical tests
Sundar B N

chapter 2 stat.pptx
chapter 2 stat.pptx
ISAGANIVALEROZO

Biostatistics
Biostatistics

Assumptions of ANOVA
Assumptions of ANOVA
richardchandler

One Way Anova
One Way Anova
shoffma5

parametric test of difference z test f test one-way_two-way_anova
parametric test of difference z test f test one-way_two-way_anova
Tess Anoza

Analysis of Variance (ANOVA), MANOVA: Expected variance components, Random an...
Analysis of Variance (ANOVA), MANOVA: Expected variance components, Random an...

Chi square test
Chi square test
YASMEEN CHAUDHARI

Analysis of Variance
Analysis of Variance
jyothimonc

Parametric tests
Parametric tests
Shivankan Kakkar

t test using spss
t test using spss
Parag Shah

Student t-test
Student t-test
Steve Bishop

### What's hot(19)

One way anova
One way anova

ANOVA-One Way Classification
ANOVA-One Way Classification

Statistical analysis by iswar
Statistical analysis by iswar

Sampling distribution
Sampling distribution

Student t test
Student t test

Test of significance
Test of significance

Posthoc
Posthoc

Parametric Statistical tests
Parametric Statistical tests

chapter 2 stat.pptx
chapter 2 stat.pptx

Biostatistics
Biostatistics

Assumptions of ANOVA
Assumptions of ANOVA

One Way Anova
One Way Anova

parametric test of difference z test f test one-way_two-way_anova
parametric test of difference z test f test one-way_two-way_anova

Analysis of Variance (ANOVA), MANOVA: Expected variance components, Random an...
Analysis of Variance (ANOVA), MANOVA: Expected variance components, Random an...

Chi square test
Chi square test

Analysis of Variance
Analysis of Variance

Parametric tests
Parametric tests

t test using spss
t test using spss

Student t-test
Student t-test

## Viewers also liked

Actor Portfolio
Actor Portfolio
Vic Divecha

Unless It Was a Digital Dog, No One Ate Your Homework (Diigo)
Unless It Was a Digital Dog, No One Ate Your Homework (Diigo)
Lisa Sjogren

Art History
Art History
Pam McClure

Electricity Power Point
Electricity Power Point
room112008

Master programs
Master programs
akshay wal

Material de estudio
Material de estudio
Juan Carlos Monzón Arévalo

Climate Justice Launch Events
Climate Justice Launch Events
CAFOD

Christianity and the Workplace
Christianity and the Workplace
Jonathan Swales

Dr. William Allan Kritsonis - Regular School Disciplikne, Suspension, and Exp...
Dr. William Allan Kritsonis - Regular School Disciplikne, Suspension, and Exp...
William Kritsonis

Samsung: Universe Campaign Concepts (Strategy)
Samsung: Universe Campaign Concepts (Strategy)
Jessica Legg

Dr. William Allan Kritsonis - Personnel Issues PPT.
Dr. William Allan Kritsonis - Personnel Issues PPT.
William Kritsonis

Dr. William Allan Kritsonis - Personnel Issues PPT.
Dr. William Allan Kritsonis - Personnel Issues PPT.
William Kritsonis

Pakistan - six months on
Pakistan - six months on
CAFOD

Copyright Laws PPT. - William Allan Kritsonis, PhD
Copyright Laws PPT. - William Allan Kritsonis, PhD
William Kritsonis

การระดมทุนจาก CrowdFunding
การระดมทุนจาก CrowdFunding
Sathittham Sangthong

Chapter11[1]
Chapter11[1]
William Kritsonis

Dr. William Allan Kritsonis - What the Law Says About Curriculum Issues PPT.
Dr. William Allan Kritsonis - What the Law Says About Curriculum Issues PPT.
William Kritsonis

Court Case 1
Court Case 1
William Kritsonis

Epidemiology of physical activity in the Middle East
Epidemiology of physical activity in the Middle East
Tarek Tawfik Amin

Beaver-Results Austria
Beaver-Results Austria
Peter Micheuz

### Viewers also liked(20)

Actor Portfolio
Actor Portfolio

Unless It Was a Digital Dog, No One Ate Your Homework (Diigo)
Unless It Was a Digital Dog, No One Ate Your Homework (Diigo)

Art History
Art History

Electricity Power Point
Electricity Power Point

Master programs
Master programs

Material de estudio
Material de estudio

Climate Justice Launch Events
Climate Justice Launch Events

Christianity and the Workplace
Christianity and the Workplace

Dr. William Allan Kritsonis - Regular School Disciplikne, Suspension, and Exp...
Dr. William Allan Kritsonis - Regular School Disciplikne, Suspension, and Exp...

Samsung: Universe Campaign Concepts (Strategy)
Samsung: Universe Campaign Concepts (Strategy)

Dr. William Allan Kritsonis - Personnel Issues PPT.
Dr. William Allan Kritsonis - Personnel Issues PPT.

Dr. William Allan Kritsonis - Personnel Issues PPT.
Dr. William Allan Kritsonis - Personnel Issues PPT.

Pakistan - six months on
Pakistan - six months on

Copyright Laws PPT. - William Allan Kritsonis, PhD
Copyright Laws PPT. - William Allan Kritsonis, PhD

การระดมทุนจาก CrowdFunding
การระดมทุนจาก CrowdFunding

Chapter11[1]
Chapter11[1]

Dr. William Allan Kritsonis - What the Law Says About Curriculum Issues PPT.
Dr. William Allan Kritsonis - What the Law Says About Curriculum Issues PPT.

Court Case 1
Court Case 1

Epidemiology of physical activity in the Middle East
Epidemiology of physical activity in the Middle East

Beaver-Results Austria
Beaver-Results Austria

## Similar to Displaying your results

Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011
NES

bio statistics for clinical research
bio statistics for clinical research
Ranjith Paravannoor

Biostatistics
Biostatistics
Larry Baum

Why to know statistics
Why to know statistics
Hesham Gaber

Statistics
Statistics
fracpractice

Stat
Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015
Isla Kuhn

Medpage guide-to-biostatistics
Medpage guide-to-biostatistics
Elsa von Licy

Analysis and Interpretation
Analysis and Interpretation
Francisco J Grajales III

Quantitative_analysis.ppt
Quantitative_analysis.ppt

Risk Comparison
Risk Comparison
Weam Banjar

Sample size &amp; meta analysis
Sample size &amp; meta analysis
drsrb

Why to know statistics
Why to know statistics
Hesham Al-Inany

Sample size estimation
Sample size estimation
HanaaBayomy

Practical Methods To Overcome Sample Size Challenges
Practical Methods To Overcome Sample Size Challenges
nQuery

Unit 9b. Sample size estimation.ppt
Unit 9b. Sample size estimation.ppt
shakirRahman10

How to do the maths
How to do the maths
Ahmed Elfaitury

Copenhagen 2008
Copenhagen 2008
Jonas Ranstam PhD

Sample Size Determination.23.11.2021.pdf
Sample Size Determination.23.11.2021.pdf
statsanjal

Basics of Sample Size Estimation
Basics of Sample Size Estimation
Mandar Baviskar

### Similar to Displaying your results(20)

Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011

bio statistics for clinical research
bio statistics for clinical research

Biostatistics
Biostatistics

Why to know statistics
Why to know statistics

Statistics
Statistics

Stat
Stat

Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015

Medpage guide-to-biostatistics
Medpage guide-to-biostatistics

Analysis and Interpretation
Analysis and Interpretation

Quantitative_analysis.ppt
Quantitative_analysis.ppt

Risk Comparison
Risk Comparison

Sample size &amp; meta analysis
Sample size &amp; meta analysis

Why to know statistics
Why to know statistics

Sample size estimation
Sample size estimation

Practical Methods To Overcome Sample Size Challenges
Practical Methods To Overcome Sample Size Challenges

Unit 9b. Sample size estimation.ppt
Unit 9b. Sample size estimation.ppt

How to do the maths
How to do the maths

Copenhagen 2008
Copenhagen 2008

Sample Size Determination.23.11.2021.pdf
Sample Size Determination.23.11.2021.pdf

Basics of Sample Size Estimation
Basics of Sample Size Estimation

## More from Tarek Tawfik Amin

Publishing of an article
Publishing of an article
Tarek Tawfik Amin

Blinding in clinical trilas
Blinding in clinical trilas
Tarek Tawfik Amin

Clincal trails phases
Clincal trails phases
Tarek Tawfik Amin

Clinical trials designs
Clinical trials designs
Tarek Tawfik Amin

Scientific writing
Scientific writing
Tarek Tawfik Amin

Bias and confounding
Bias and confounding
Tarek Tawfik Amin

Data collection
Data collection
Tarek Tawfik Amin

Cancer Epidemiology part II
Cancer Epidemiology part II
Tarek Tawfik Amin

Cancer Epidemiology part I
Cancer Epidemiology part I
Tarek Tawfik Amin

Community Diagnosis
Community Diagnosis
Tarek Tawfik Amin

Ebola virus disease
Ebola virus disease
Tarek Tawfik Amin

Linear Correlation
Linear Correlation
Tarek Tawfik Amin

Plagiarism
Plagiarism
Tarek Tawfik Amin

Screening test (basic concepts)
Screening test (basic concepts)
Tarek Tawfik Amin

Public awareness
Public awareness
Tarek Tawfik Amin

Tarek Tawfik Amin

Breast cancer risk factors
Breast cancer risk factors
Tarek Tawfik Amin

Types of epidemics and epidemic investigations
Types of epidemics and epidemic investigations
Tarek Tawfik Amin

Samples Types and Methods
Samples Types and Methods
Tarek Tawfik Amin

Competency based education in Public Health
Competency based education in Public Health
Tarek Tawfik Amin

### More from Tarek Tawfik Amin(20)

Publishing of an article
Publishing of an article

Blinding in clinical trilas
Blinding in clinical trilas

Clincal trails phases
Clincal trails phases

Clinical trials designs
Clinical trials designs

Scientific writing
Scientific writing

Bias and confounding
Bias and confounding

Data collection
Data collection

Cancer Epidemiology part II
Cancer Epidemiology part II

Cancer Epidemiology part I
Cancer Epidemiology part I

Community Diagnosis
Community Diagnosis

Ebola virus disease
Ebola virus disease

Linear Correlation
Linear Correlation

Plagiarism
Plagiarism

Screening test (basic concepts)
Screening test (basic concepts)

Public awareness
Public awareness

Breast cancer risk factors
Breast cancer risk factors

Types of epidemics and epidemic investigations
Types of epidemics and epidemic investigations

Samples Types and Methods
Samples Types and Methods

Competency based education in Public Health
Competency based education in Public Health

Test Bank For Principles Of Cost Accounting, 17th Edition Edward J. Vander...
Test Bank For Principles Of Cost Accounting, 17th Edition Edward J. Vander...
kevinkariuki227

KineMaster Diamond APK v7.3.11.32200 (4K HD, No Watermark)
KineMaster Diamond APK v7.3.11.32200 (4K HD, No Watermark)
APKs Pure

TALENT ACQUISITION AND MANAGEMENT LECTURE 2
TALENT ACQUISITION AND MANAGEMENT LECTURE 2
projectseasy

The IIT Madras Product Management Casebook 23-24.pdf
The IIT Madras Product Management Casebook 23-24.pdf
Keerthiraja11

brojjeddah Home Services Company in Saudi Arabia
brojjeddah Home Services Company in Saudi Arabia
brojjeddah

Importance of Quality Transformations in VUCA World
Importance of Quality Transformations in VUCA World
Ankur860831

Case study on Indian Ecommerce logistics
Case study on Indian Ecommerce logistics
UnheardShayari

BBA Final SML 501 INTERNATIONAL BUSINESS .pdf
BBA Final SML 501 INTERNATIONAL BUSINESS .pdf
mcdopex6

Anton Grutzmache- Ominisient: The Data Revolution in Banking: From Scoring Cr...
Anton Grutzmache- Ominisient: The Data Revolution in Banking: From Scoring Cr...
itnewsafrica

Connected Small Boat Protection Solution | July 2024
Connected Small Boat Protection Solution | July 2024
Hector Del Castillo, CPM, CPMM

A Complete Guide of Dubai Freelance Visa and Permit in 2024
A Complete Guide of Dubai Freelance Visa and Permit in 2024
Dubiz

Innovation Hub_ Spotlight on Toms River's Role as a Beacon for Entrepreneuria...
Innovation Hub_ Spotlight on Toms River's Role as a Beacon for Entrepreneuria...
Philip M Caputo

Cheslyn Jacobs- TymeBank: Building Consumer Trust in Digital Banking
Cheslyn Jacobs- TymeBank: Building Consumer Trust in Digital Banking
itnewsafrica

MEA Union Budget 2024-25 Final Presentation
MEA Union Budget 2024-25 Final Presentation
PhysicsUtu

TALENT ACQUISITION AND MANAGEMENT LECTURE 5
TALENT ACQUISITION AND MANAGEMENT LECTURE 5
projectseasy

Family/Indoor Entertainment Centers Market: Regulation and Compliance Updates
Family/Indoor Entertainment Centers Market: Regulation and Compliance Updates

21stcenturyskillsframeworkfinalpresentation2-240509214747-71edb7ee.pdf
21stcenturyskillsframeworkfinalpresentation2-240509214747-71edb7ee.pdf
emmanuelpulido003

PETAVIT SIP-05.pdfAAAAAAAAAAAAAAAAAAAAAAAAA
PETAVIT SIP-05.pdfAAAAAAAAAAAAAAAAAAAAAAAAA

Green Minimalist Aesthetic Project Proposal Presentation.pdf
Green Minimalist Aesthetic Project Proposal Presentation.pdf
shivamkush646

Growth Buyouts - The Dawn of the GBO (Slow Ventures)
Growth Buyouts - The Dawn of the GBO (Slow Ventures)
Razin Mustafiz

Test Bank For Principles Of Cost Accounting, 17th Edition Edward J. Vander...
Test Bank For Principles Of Cost Accounting, 17th Edition Edward J. Vander...

KineMaster Diamond APK v7.3.11.32200 (4K HD, No Watermark)
KineMaster Diamond APK v7.3.11.32200 (4K HD, No Watermark)

TALENT ACQUISITION AND MANAGEMENT LECTURE 2
TALENT ACQUISITION AND MANAGEMENT LECTURE 2

The IIT Madras Product Management Casebook 23-24.pdf
The IIT Madras Product Management Casebook 23-24.pdf

brojjeddah Home Services Company in Saudi Arabia
brojjeddah Home Services Company in Saudi Arabia

Importance of Quality Transformations in VUCA World
Importance of Quality Transformations in VUCA World

Case study on Indian Ecommerce logistics
Case study on Indian Ecommerce logistics

BBA Final SML 501 INTERNATIONAL BUSINESS .pdf
BBA Final SML 501 INTERNATIONAL BUSINESS .pdf

Anton Grutzmache- Ominisient: The Data Revolution in Banking: From Scoring Cr...
Anton Grutzmache- Ominisient: The Data Revolution in Banking: From Scoring Cr...

Connected Small Boat Protection Solution | July 2024
Connected Small Boat Protection Solution | July 2024

A Complete Guide of Dubai Freelance Visa and Permit in 2024
A Complete Guide of Dubai Freelance Visa and Permit in 2024

Innovation Hub_ Spotlight on Toms River's Role as a Beacon for Entrepreneuria...
Innovation Hub_ Spotlight on Toms River's Role as a Beacon for Entrepreneuria...

Cheslyn Jacobs- TymeBank: Building Consumer Trust in Digital Banking
Cheslyn Jacobs- TymeBank: Building Consumer Trust in Digital Banking

MEA Union Budget 2024-25 Final Presentation
MEA Union Budget 2024-25 Final Presentation

TALENT ACQUISITION AND MANAGEMENT LECTURE 5
TALENT ACQUISITION AND MANAGEMENT LECTURE 5

Family/Indoor Entertainment Centers Market: Regulation and Compliance Updates
Family/Indoor Entertainment Centers Market: Regulation and Compliance Updates

21stcenturyskillsframeworkfinalpresentation2-240509214747-71edb7ee.pdf
21stcenturyskillsframeworkfinalpresentation2-240509214747-71edb7ee.pdf

PETAVIT SIP-05.pdfAAAAAAAAAAAAAAAAAAAAAAAAA
PETAVIT SIP-05.pdfAAAAAAAAAAAAAAAAAAAAAAAAA

Green Minimalist Aesthetic Project Proposal Presentation.pdf
Green Minimalist Aesthetic Project Proposal Presentation.pdf

Growth Buyouts - The Dawn of the GBO (Slow Ventures)
Growth Buyouts - The Dawn of the GBO (Slow Ventures)

• 1. Displaying Your Results Dr Tarek Amin Professor of Public Health Cairo University amin55@myway.com
• 2. Are you Currently engaged in research? Intention to publish in indexed journals?
• 3. M istakes Could H appen!!!  Confusing between data and information in the results section.  Inclusion of too many pieces of data which may obscure the important stuff.  Inclusion of the mean, median, standard deviation, range, confidence interval, standard error and others for every measured variable studied.  Writing a manuscript around a significant P value.  Relying on statistical jargon instead of E nglish to describe the results.
• 4. Supported by CI “precision of what you found” E ffect size “what you found” Cameo appearance of the carrierfading P value. If needed, add adjusted analyses “the exploration of alternative explanation” P repare the stage
• 6. Statistics: Descriptive Results Involve only one variable, either predictor or an outcome types of Descriptive DAtA Categorical Dichotomous B inary data Continuous data L imited number of mutually exclusive possibilities Data having > 6 ordered values F ollow a logical order or rank Do not have a logical sequence Ordinal Nominal
• 7. 1-Describing Dichotomous and Categorical Variables P ercentage Standardize your data for easy comparison P roportions Risks, rates and Odds Numerical expression compares one part of the study units to the whole “expressed in fractions or decimals” (male patients represented 2/ of our study subjects) 3 P rovide both the numerator and denominator: (4/ and 400/ 10 1000) = 40% Indicate precision using appropriate number of digits: (4/ = 18.2% 22 not 18.0%) Do not use % when the denominator is small: (< 50 subjects). W dichotomous variables only one value is needed: ith (after 3 years, 44% (86/ 196) of the subjects were still alive) F categorical variables, provide all % within categories: or (we found that 12 % of the subjects had poor health, 23% had fair health
• 8. Risks, Rates, and Odds estimates of the frequency of a dichotomous outcome in a group of subje who have been followed for a period of time. A study of 5000 people who were followed for 2 years to see who developed lung cancer, and among them 80 new cases occurred. Risk Number who develop outcome Number at risk Odds 80 Number who develop outcome = = 0.016 5000 Number at risk who do not develop outcome In cross-sectional study = prevalence = Number with a characteristic T otal number R ate 80 = 4920 = 0.0163 Used in case-control study /in performing logistic regression. Number who develop outcome 80 = P erson-time at risk = 0.008 / person4920 * 2 = 9940 Risk and Odds are roughly the same if the outcome occur in less 10 %, and similar to rate multiplied by the average amount of follow up.
• 10. 2- Describing Continuous Variables Using Measures of average and spread 1- E xamine your data M easures of skewness Using a graph 10 No. of 5 women 100 37.51-40.00 35.51-37.50 32.51-35.00 30.01-32.50 27.51-30.00 25.01-27.50 22.51-25.00 20.01-22.50 17.51-20.00 0 15.01-17.5 0 Number 50 of men age of the mother 0 1 2 3 4 5 6 7 8 9 Triglyceride level Non-normal distribution Normal distribution
• 11. M easures of skewness or symmetry Pearson’s skewness Coefficient Skewness = (mean-median)/ SD 0 = perfectly symmetrical > + 0.2 or < - 0.2 indicate severe skewness F isher’s measure of skewness Deviation of the mean to the third power, done by computer. A value close to 0 = normal distribution > + 1.96 or < - 1.96 indicate significant skewness 2- Description Normal distribution Non-normal distribution M ean Standard deviation M edian Inter-quartile range M easures of average and spread: P rovide information about the population from which your sample was chosen, and to which your results may apply.
• 12. Statistics: Analytic Results Rules Compare two or more variables or groups.  F decide who should be compared “intention to treat” irst or “once randomized always analyzed”.  Comparing “like with like”.  M aking comparison between groups rather within groups “placebo versus study groups rather than change occurred within study group after intervention”  Compare independent sampling units “five episodes of angiodema in a single patient should not be counted as a five sampling units”  Compare the effect size.
• 13. M ood changes of residents and interns on the day after being on call. Characteristics Alert in rounds M ood H appy Neutral Sad Sleep (mean hr / night) Interns (n=40) Residents (n=20) P value 40 % 60% 0.020 20% 30% 50% 4.2 40% 30% 30% 6.8 0.030 0.012 0.001 E ffect size: Residents are 1.5 times as likely to be alert (60% / 40%=1.5) or 20% more likely to be alert. Interns are 0.67 times as likely to be alert. void writing the results section around a significant P value.
• 14. Effect Size “approach” ¶ L the 5 or 10 most essential analytic ‘key’ results in ist your study “brevity is a virtue”. ¶ Decide which is the predictor (independent) variable, and which is the outcome variable, for each. ¶ Decide whether predictor and outcome variables are dichotomous, categorical, or continuous. ¶ Decide what sort of effect size to use, based on the type of predictor, outcome variables and study design.
• 15. E ffect size measurements P redictor variable Outcome variable Dichotomous Dichotomous M (vs. ale female) Antistroke drug (vs. placebo) H ypertension (SB > 160 or P DB >90) P ‘Cross-sectional’ Stroke in the next 2 years Clinical trial E ffect size Relative prevalence = proportion of men “hypertensive” proportion of women “hypertensive Difference in prevalence = proportion of hypertensive men – Relative risk (risk ratio) Risk difference Use of saccharine (vs. non-use) B ladder cancer (vs. control) Vertebral fracture (vs. no vertebral fracture) * In cohort design: F ormula proportion of hypertensive women = risk of stroke in persons treated with drug risk of stroke in placebo group = risk of stroke in the treated – risk in placebo B ladder cancer in the next 20 years Cohort study Odds ratio /RR* = odds of cancer in users of saccharine odds of cancer in non-users Use of saccharine in the previous 20 years Case-control Odds ratio = odds of saccharine use in cases of cancer odds of saccharine use in controls Rate ratio = hip fracture rate in those with vertebral H fracture in the (relative ip fractures next 5 years hazard) hip fracture rate in those w/ vertebral o Survival analysis fractures relative risk and Odds ratio could be used. Rate difference = rate of hip fracture in those with vertebral
• 16. E ffect size measurements P redictor variable Outcome variable Dichotomous Continuous W hite (vs. non white) Systolic blood pressure (SB ) P Case-control / Cohort New drug (vs. placebo) Change in diastolic blood pressure (DB ) P Clinical trial Continuous E ffect size M ean difference M ean % difference” F ormula = mean SB in whites – mean SB in non P P whites = mean SB in white – mean SB in non P P whites mean SB in non white P Continuous M ean difference in change Creatinine clearance 1, 25- vitamin D level Regression/ Slope Serum lead level IQ P roportion of variance explained = mean change in DB in treatment group – P mean change in DB in placebo group P Change in 1, 25 Vitamin D level per change in creatinine clearance Correlation between lead level and IQ
• 17. T conclude o Simple effect size for dichotomous predictor and dichotomous outcome variables Depends primarily on the study design: β Cross-sectional = prevalence β Case-control = Odds ratios β Cohort or randomized trial = risk, rate, Odds, or risk or rate differences.
• 18. Risk ratio: how many times more likely an event was to occur in one group than in another: a risk ratio of 2.23 (123%) greater risk (or 2.23 folds). T conclude o Risk ratios (odds ratio and rate ratios) that are less than 1 can be difficult to interpret. Risk difference: how much more likely an outcome is to happen in one group than in another ‘a risk difference of 1 % means that of 100 subjects, one less event occurred in one of the group’. Number needed to treat= 1/risk difference.
• 19. T conclude o Odds difference do not make sense , when comparing odds, only the odds ratio is useful. W hen the outcome is rare (< 10%): Odds ratios, risk ratios, and rate ratios are similar. W hen the outcome is > 30 %: the three measures are very different.
• 20. M ore complicated ways for dichotomy Logistic regression W hen the time to the outcome is not known or does not matter. Used to delineate the possible predictor for the outcome It yields Odds ratios. Cox proportional hazard model Used when the time to the event is known and matters. Useful when the amount of follow up varies among the subjects “E nrolled at different times, dropped out or died of unrelated causes”. It yields rate (hazard) ratio. Survival analysis Nothing to do with living or dying. Remaining free of the outcome of interest Used whether the outcome is fatal or not “disease free survival”. Now, I know how you feel.
• 21. T conclude o E ffect size for Dichotomous predictors and Continuous outcome variable Distribution Normal Compare means M ean difference is the effect size Absolute or % difference could be used Non-normal Compare medians Or use non-parametric tests
• 22. E ffect size for Continuous predictor and Continuous outcome L inear regression Correlation Or others T conclude o
• 23. Indicating the precision of your estimates with Confidence Intervals. • It is the range of values that are consistent with your estimate. • 95% CI= repeating of bias-free study many times, 95 % of all the CI for the point estimate “ your finding” will contain the true value of the population. • The wider a CI, the less precise is the point estimate.
• 24. Relation between CI and P value T concept of NO E F CT he FE . E ffect size measured as No effect “insignificant P value” Difference in prevalence Risk difference Rate difference Number needed to treat M ean difference M ean % difference M ean change M ean % change Slope Correlation P revalence ratio Risk ratio Odds ratio Rate ratio 0 0 0 ზ 0 0 0 0 0 0 1 1 1 1
• 25. E xamples • M ean difference in serum bicar. level between 2 groups is 5 meq/ (95% CI of L 2-8) = the difference is significant because it does not include the NO E F CT ‘0’. FE • T relative risk of osteosarcoma in he smokers is 2.0 (95% CI, 1.0-4.0)= P value is > o.o5. • Odds ratio is 1.4 (95 % CI= 1.1-3.9)= the P value is significant because it does not include the no effect= 1.
• 26. W here the P value come from? • Statistical tests of significance: • W hat, when, why and how? Next table. • Actual P value should be provided: (P = 0.034 rather P < 0.05) or (P = 0.098 rather P > 0.05 or NS). • Do not compare the P value. • Use the P value wisely: not more than 1015.
• 27. Road map for statistical tests of significance T ype of Data Goal of the test Measurement (continuous) Rank, Score, or M easurement (nonnormal) B inomial (T P wo ossible Outcomes) Survival T ime Describe one group M ean, SD M edian, interquartile range P roportion K aplan M eier survival curve Compare one group to a hypothetical value One-sample t test W ilcoxon test Chi-square or B inomial test * * Compare two unpaired groups Unpaired t test M ann-W hitney test F isher's test (chi-square for large samples) L og-rank test or M antelH aenszel* Compare two paired groups P aired t test W ilcoxon test M cNemar's test Conditional proportional hazards regression* Compare three or more unmatched groups One-way ANOVA K ruskal-W allis test Chi-square test Cox proportional hazard regression* * Compare three or more matched groups Repeated-measures ANOVA F riedman test Cochrane Q* * Conditional proportional hazards regression* * Quantify association between two variables P earson correlation Spearman correlation Contingency coefficients* * P redict value from another measured variable Simple linear regression or Nonlinear regression Nonparametric regression* * Simple logistic regression* Cox proportional hazard regression* P redict value from M ultiple linear M ultiple logistic Cox proportional
• 28. PARAM T E RIC AND NONP ARAM T E RIC T ST E S You should definitely choose a parametric test if you are sure that your data are sampled from a population that follows a Gaussian “normal” distribution (at least approximately)
• 29. Select a nonparametric test in three situations: Ω T outcome is a rank or a score and the he population is clearly not Gaussian. E xamples include class ranking of students, Apgar score, visual analogue score for pain, and star* * * scale. Ω Some values are "off the scale" that is, too high or too low to measure. E xcess extremes. Ω T data ire measurements, and you are sure he that the population is not distributed in a Gaussian manner “biological fluids or markers”
• 30. P ARAM T E RIC AND NONP ARAM T E RIC T ST T E E S: H H ARD W AY. A formal statistical test (K olmogorov-Smirnoff test) can be used to test whether the distribution of the data differs significantly from a Gaussian distribution.
• 31. Conclusions: • Identify the type of your variables. • Define which are the predictors and which are the outcomes. • Use the effect size in description of your results. • E stimate the 95% confidence intervals for your estimates for better precision. • Use the P value wisely and do not let it steal the show.
Current LanguageEnglish
Español
Portugues
Français
Deutsche